330 related articles for article (PubMed ID: 26794000)
1. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
2. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
3. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
[TBL] [Abstract][Full Text] [Related]
4. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
5. A Role for VCP/p97 in the Processing of Drug-Stabilized TOP2-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2021 Jul; 100(1):57-62. PubMed ID: 33941661
[TBL] [Abstract][Full Text] [Related]
6. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
8. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
Elife; 2020 Feb; 9():. PubMed ID: 32057297
[TBL] [Abstract][Full Text] [Related]
9. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
10. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
Fox ME; Smith PJ
Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway.
Toh YM; Li TK
Clin Cancer Res; 2011 Aug; 17(15):5026-37. PubMed ID: 21653687
[TBL] [Abstract][Full Text] [Related]
12. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
14. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
15. FEN1 participates in repair of the 5'-phosphotyrosyl terminus of DNA single-strand breaks.
Kametani Y; Takahata C; Narita T; Tanaka K; Iwai S; Kuraoka I
Carcinogenesis; 2016 Jan; 37(1):56-62. PubMed ID: 26581212
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
17. Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide.
Tammaro M; Barr P; Ricci B; Yan H
PLoS One; 2013; 8(11):e79202. PubMed ID: 24244448
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
19. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
20. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
